U.S. Markets closed

NanoViricides announces DengueCide evaluation contract renewal

NanoViricides announced that the DengueCide evaluation contract has been renewed with Doctor Eva Harris’ Laboratory at the University of California, Berkeley, School of Public Health, Division of Infectious Diseases and Vaccinology. This contract renewal will allow the company to continue its drug development program for the treatment of dengue. The FDA has recently awarded orphan drug status to DengueCide and the company is pursuing similar status with the European Medicines Agency.